Dr. William B. White, MD
Internal Medicine (Hypertension Specialist Physician)
At a glance
- In the NPI registry since
- 2005
Licensed in Connecticut since 1979, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hypertension Specialist Physician primary
CT license 021723 (first issued 1979; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 9 companies reported 58 payments worth $398,625 in total to this clinician.
| Sumitomo Pharma America, Inc. | $222,530 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $40,868 |
| Alnylam Pharmaceuticals Inc. | $40,837 |
| Takeda Pharmaceuticals U.S.A., Inc. | $34,856 |
| AstraZeneca UK Limited | $23,394 |
| UCB SA | $13,800 |
| Vertex Pharmaceuticals Incorporated | $11,725 |
| Jazz Pharmaceuticals Inc. | $5,738 |
| Consulting Fee | $398,625 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. Mar 20, 2025 | Consulting Fee | $51,675 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $31,540 |
| Sumitomo Pharma America, Inc. Sep 25, 2025 | Consulting Fee | $24,375 |
| Sumitomo Pharma America, Inc. Dec 4, 2025 | Consulting Fee | $20,543 |
| Sumitomo Pharma America, Inc. Sep 11, 2025 | Consulting Fee | $16,808 |
| Sumitomo Pharma America, Inc. May 15, 2025 | Consulting Fee | $14,138 |
| Sumitomo Pharma America, Inc. Jul 17, 2025 | Consulting Fee | $14,138 |
| Sumitomo Pharma America, Inc. Aug 14, 2025 | Consulting Fee | $11,863 |
| Sumitomo Pharma America, Inc. Apr 3, 2025 | Consulting Fee | $9,913 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 10, 2025 | Consulting Fee | $9,831 |
All 58 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Dec 18, 2025 | Consulting Fee | $5,156 |
| Alnylam Pharmaceuticals Inc. Dec 18, 2025 | Consulting Fee | $4,847 |
| Sumitomo Pharma America, Inc. Dec 4, 2025 | Consulting Fee | $20,543 |
| AstraZeneca UK Limited Nov 25, 2025 | Consulting Fee | $1,744 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 24, 2025 | Consulting Fee | $2,503 |
| Sumitomo Pharma America, Inc. Nov 20, 2025 | Consulting Fee | $5,603 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 10, 2025 | Consulting Fee | $9,831 |
| Vertex Pharmaceuticals Incorporated Oct 29, 2025 | Consulting Fee | $1,575 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 17, 2025 | Consulting Fee | $8,223 |
| Sumitomo Pharma America, Inc. Oct 16, 2025 | Consulting Fee | $31,540 |
| AstraZeneca Pharmaceuticals LP Oct 15, 2025 | Consulting Fee | $7,500 |
| Alnylam Pharmaceuticals Inc. Oct 9, 2025 | Consulting Fee | $5,111 |
| AstraZeneca UK Limited Oct 9, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity | $2,325 |
| Sumitomo Pharma America, Inc. Sep 25, 2025 | Consulting Fee | $24,375 |
| Sumitomo Pharma America, Inc. Sep 11, 2025 | Consulting Fee | $16,808 |
| UCB SA Aug 22, 2025 | Consulting Fee Bimzelx · Immunology | $5,100 |
| Sumitomo Pharma America, Inc. Aug 14, 2025 | Consulting Fee | $11,863 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 18, 2025 | Consulting Fee | $5,363 |
| Sumitomo Pharma America, Inc. Jul 17, 2025 | Consulting Fee | $14,138 |
| AstraZeneca Pharmaceuticals LP Jul 15, 2025 | Consulting Fee | $4,500 |
| AstraZeneca Pharmaceuticals LP Jul 15, 2025 | Consulting Fee | $4,125 |
| Alnylam Pharmaceuticals Inc. Jul 10, 2025 | Consulting Fee | $4,406 |
| Sumitomo Pharma America, Inc. Jun 26, 2025 | Consulting Fee | $5,525 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 18, 2025 | Consulting Fee | $4,290 |
| Sumitomo Pharma America, Inc. Jun 12, 2025 | Consulting Fee | $3,900 |
| Alnylam Pharmaceuticals Inc. Jun 5, 2025 | Consulting Fee | $4,583 |
| AstraZeneca UK Limited Jun 5, 2025 | Consulting Fee | $350 |
| Sumitomo Pharma America, Inc. May 29, 2025 | Consulting Fee | $5,525 |
| Sumitomo Pharma America, Inc. May 15, 2025 | Consulting Fee | $14,138 |
| Alnylam Pharmaceuticals Inc. May 15, 2025 | Consulting Fee | $5,630 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Consulting Fee | $5,438 |
| Alnylam Pharmaceuticals Inc. May 15, 2025 | Consulting Fee | $4,230 |
| AstraZeneca UK Limited May 14, 2025 | Consulting Fee | $4,225 |
| AstraZeneca UK Limited May 9, 2025 | Consulting Fee | $5,525 |
| AstraZeneca UK Limited May 2, 2025 | Consulting Fee | $2,906 |
| UCB SA May 2, 2025 | Consulting Fee Bimzelx · Immunology | $2,700 |
| AstraZeneca UK Limited Apr 28, 2025 | Consulting Fee | $2,906 |
| Takeda Pharmaceuticals U.S.A., Inc. Apr 25, 2025 | Consulting Fee | $4,648 |
| Sumitomo Pharma America, Inc. Apr 17, 2025 | Consulting Fee | $3,088 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Consulting Fee | $8,063 |
| Vertex Pharmaceuticals Incorporated Apr 9, 2025 | Consulting Fee | $5,075 |
| Sumitomo Pharma America, Inc. Apr 3, 2025 | Consulting Fee | $9,913 |
| AstraZeneca UK Limited Apr 1, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity | $1,463 |
| Sumitomo Pharma America, Inc. Mar 20, 2025 | Consulting Fee | $51,675 |
| Vertex Pharmaceuticals Incorporated Mar 19, 2025 | Consulting Fee | $5,075 |
| AstraZeneca Pharmaceuticals LP Mar 15, 2025 | Consulting Fee | $6,000 |
| Alnylam Pharmaceuticals Inc. Mar 6, 2025 | Consulting Fee | $3,525 |
| Alnylam Pharmaceuticals Inc. Mar 6, 2025 | Consulting Fee | $3,349 |
| AstraZeneca UK Limited Mar 5, 2025 | Consulting Fee SAPHNELO · Inflammation and Autoimmunity | $1,950 |
| Jazz Pharmaceuticals Inc. Feb 28, 2025 | Consulting Fee XYWAV · NEUROLOGY | $5,738 |
| UCB SA Feb 28, 2025 | Consulting Fee Bimzelx · Immunology | $3,450 |
| AstraZeneca Pharmaceuticals LP Feb 15, 2025 | Consulting Fee | $248 |
| AstraZeneca Pharmaceuticals LP Feb 15, 2025 | Consulting Fee | $248 |
| AstraZeneca Pharmaceuticals LP Feb 15, 2025 | Consulting Fee | $248 |
| Sumitomo Pharma America, Inc. Feb 13, 2025 | Consulting Fee | $3,900 |
| UCB SA Jan 31, 2025 | Consulting Fee Bimzelx · Immunology | $2,550 |
| AstraZeneca Pharmaceuticals LP Jan 15, 2025 | Consulting Fee | $4,500 |
| Sanofi US Services Inc. Jan 13, 2025 | Consulting Fee | $4,878 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.